Advancements in microbiome research reveal its impact on cancer treatment outcomes, particularly in renal cell carcinoma (RCC). While immune checkpoint inhibitors (ICIs) have improved survival in metastatic RCC, composition of the gut microbiome has the potential to influence their efficacy.
Antibiotic-induced microbiome disruptions correlate with diminished outcomes, while strains such as Akkermansia muciniphila, Clostridium butyricum, and others enhance immune responses and progression-free survival. Some prebiotics such as inulin gel can alter the gut flora to overcome the resistant strains occurring in response to immune therapy. This mini-review explores microbiome-targeted interventions, such as pre/probiotics and fecal microbiota transplantation, for overcoming ICI resistance. Although promising, prospective randomized trials are needed to standardize clinical applications and optimize microbiome-targeted treatments. The standard use of gut-modulating therapy cannot be recommended at present outside of clinical trials. A double-blind placebo-controlled randomized trial of ICI ± gut modulating therapy is being planned in frontline therapy of advanced RCC (BIOFRONT trial by the Southwest Oncology Group).
European urology focus. 2025 Jan 16 [Epub ahead of print]
Sara Elyas, Pedro Barata, Ulka Vaishampayan
Lyman Briggs College, Michigan State University, East Lansing, MI, USA., University Hospitals Seidman Cancer Center, Cleveland, OH, USA., Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/39824679